Gsk Share Discussion Threads

[paul planet earth] 22/9/2022 21:19

Hands up anyone who thought spinning off the Consumer Business was a success for half the price Unilever offered?

[lovewinshatelosses] 22/9/2022 10:07

Lies, dam lies and broker notes :) I do not see a 50% upside in this market, let alone the market of 2023, but if I get the chance to get back in, I would be satisfied with 25% or so. If the business looks like it is finally going to become the real heavy hitter that many of us hoped in previous years, I would happily add it to my long term hold stocks again. But that is to be seen....

[tradermichael] 22/9/2022 09:59

I should say a 50% discount to previously projected price would be a gift .... ;0)

[lovewinshatelosses] 22/9/2022 09:55

1200 would probably be the time I returned to GSK, in spite of my (IMO justified) lack of faith in EW. Unless some further bad company-specific news came up, I think that would represent a price too low to ignore.

[tradermichael] 22/9/2022 09:32

Yes, and GSK in an earlier life was a leader in UT infection treatments (e.g. TMP).

[alphorn] 22/9/2022 09:08

GSK were leaders in the antibiotic field, now they are buying in candidates.
Also note that the upfront payments to Spero and the capital payments, all representing past R&D costs by Spero will go onto the GSK balance sheet.

[spoole5] 22/9/2022 09:03

Overseeing such a disaster of a demerger and keeping your job is nothing short of a disgrace.

[supermarky] 22/9/2022 09:02

it is really hard to ignore that big fat 1200 on the charts mind. looking at the tea leaves

[tradermichael] 22/9/2022 08:32

Another potential winner that seems to have gone down without as much of a whimper in the market:

GSK PLC said Thursday that it has signed an exclusive license agreement with Spero Therapeutics Inc. to commercialize tebipenem HBr, an antibiotic currently in late-stage studies that may treat complicated urinary tract infections.

The pharmaceutical giant said the deal allows GSK to commercialize the treatment in all regions, except for Japan and certain other Asian countries.

The agreement includes a payment to Spero of $66 million upfront, along with potential for future milestone payments and tiered royalties.

GSK will also purchase $9 million in shares of Spero common stock, representing 7.45 million shares at a price of around $1.2 a share, it said. The purchase won't exceed the 19.99% ownership of Spero by GSK and its affiliates, it added.

Spero will start a new phase III clinical trial in 2023, following the positive U.S. Food and Drug Administration regulatory feedback on the clinical trial design.

"Tebipenem HBr complements GSK's infectious disease strategy and is consistent with our commitment to find value-enhancing opportunities to build a strong late-stage portfolio. Tebipenem HBr has a clear U.S. FDA regulatory path to potential approval, which could significantly benefit patients with complicated urinary tract infections," Chief Commercial Officer Luke Miels said.

[supermarky] 22/9/2022 08:29

overshoots to the downside and then hopefully when more positive sentiment prevails it will move back up. I have also been buying in tranches on the way down. Would love to see 1200 ish. Buy, hold and chill until sentiment changes.

[rikky72] 22/9/2022 08:26

It has happened before with this multiple times but for different reasons. The reaction is overdone imo but who knows how long it will stay at these levels. Can't realistically see it below 12 unless there are negative macroeconomic events

[berny3] 22/9/2022 08:15

I am a little at a loss with this price. Company is being punished pretty hard imo. I thought £15 was good value, then £14 and now looking at sub £13. have been adding all the way down. Putting in place a good dividend return but puzzled. Looks to me like the market is pretty dour. On the loner term looking for some optimism and a positive market reversal.

[1knocker] 21/9/2022 16:07

In this market I think you just have to be ready to trade. After holding a position for over 10 years I sold out of GSK completely earlier this year at an average of 1745. A couple of weeks ago I sold 20% of my holding in AstraZeneca at 114 (needless to say I now wish I had been more decisive and sold more), and a few days ago I bought some GSK at 1339 (and with hindsight should have waited a bit longer). Its very difficult to make any sort of educated assessment of prices in this market. I am looking for 96 to buy back into Asdra (but may settle for 100), and 1275 to buy more GSK (but if and when the price closes in on that I may hold off for 1250). Probably better though not to worry much over a a few pence; provided one makes a reasonable amount on the round trip that is really what matters, and opportunities can easily be missed by holding off too long.

[porsche1945] 21/9/2022 15:59

I take it Elliot dumped this once haleon was split off. I think reality of a basically shxt biz with no real blockbuster drugs, a ton of debt, buying the wrong stuff ( 4.5 b down the toilet on that bio med in the US a couple of years ago ) shat management, poor ceo and weak chairman, best days long gone, seems to be going the same way as the ftse 100/UK/sterling in general. Just terminal. Astra probably the next to blow up as share price running on fumes. This dividend stuff always ends in tears, think abrdn, vod, bt, MKS etc the list is endless. Once commodity prices tank next year ftse will be worth about 4800.

[zho] 21/9/2022 15:29

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

[tradermichael] 21/9/2022 15:05

Q3 results on Nov 2 had better be stunning*, with a good story to tell. Otherwise, cannot accept that Emma's position is tenable.

*e.g. Haleon posted double-digit revenue growth in its first interim results as an independently-listed company.

[spoole5] 21/9/2022 14:07

1300 to go? Hopefully Emma will follow.

[netcurtains] 21/9/2022 14:05

I told you yesterday.

[hopefuldave] 21/9/2022 14:02

Can’t believe you’re so brave to keep buying glaxo.I’m in despair at drop in share price.will it recover??.

[netcurtains] 20/9/2022 14:06

Risks of Ukraine escalation due to referendums are causing some panic in the FTSE et al.

[tradermichael] 20/9/2022 12:04

Haleon has posted double-digit revenue growth in its first interim results as an independently-listed company.
The group, which became the UK's largest stock market listing in a decade when it spun off from pharma giant GlaxoSmithKline in July, saw revenues jump 13.4 per cent to £5.19billion in the six months to 30 June as adjusted operating profits jumped 12.2 per cent to £1.19billion.
Haleon also told investors it believes it is not liable for claims arising from US litigation over heartburn drug Zantac, which has hit pharma shares significantly in recent months amid allegations the compound contains a probable carcinogen.

[supermarky] 20/9/2022 11:52

Just added another few earlier this morning. Will it go to 1200 ? If so I will definitely be a buyer.

[bracke] 18/9/2022 11:09

Good day uppompeii

I'm well in body....... if not mind.

Good luck with your portfolio.

I've been through the elderly parent phase. I empathise. No grand children as yet.

I'm still trading but rarely an overnight hold and certainly no holding over the weekends.

[tim 3] 17/9/2022 11:50

Sorry for the long term holders here what a torrid time.Still hold some via trusts.Chart wise £12 is big support not sure if they trying to get it there.